Citius Pharmaceuticals (CTXR) AI Stock Analysis

• Market Cap: $18.47M
• Dividend Yield: N/A
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: N/A
• EPS Growth: 18.73%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 22,376,427
• 10 Day Avg. Volume: 511,305
• 30 Day Avg. Volume: 1,160,981
• PEG Ratio: <0.01
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: 0.85
• Enterprise Value/Gross Profit: 1.38
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.9
• Revenue Forecast (FY): $78.00M

• Rating: 50 Neutral
• Price Target: $0.93 ▲(8.26% Upside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is primarily constrained by ongoing large losses and sustained cash burn despite a low-debt balance sheet. Technicals are neutral with a short-term bounce but longer-term weakness. Valuation is penalized by negative earnings and no dividend, while recent positive early-stage LYMPHIR trial updates provide a modest offset.

Positive Factors

Commercial launch / first product revenue

Transitioning from purely clinical-stage to generating product revenue materially de-risks the business model. Early commercial sales validate go-to-market execution, create a revenue runway to support further development, and enable scaling investments and partner negotiations over the next several quarters.

Low leverage and sizable equity base

A very low debt load and meaningful equity position provide financial flexibility to fund development, pursue partnerships, and withstand near-term operational volatility without immediate refinancing. This reduces bankruptcy risk and supports multi-quarter development and commercialization plans.

Promising investigator-initiated trial data expanding indications

Robust safety and pharmacodynamic signals in CAR-T and other investigator studies support broader immuno-oncology uses beyond the initial indication. If confirmed in larger trials, this can materially expand addressable markets, make LYMPHIR a combo-therapy platform, and attract partners or licensing opportunities.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow means the company is not self-funding growth. Continued cash burn requires recurring external financing, which can dilute shareholders, constrain strategic choices, and limit the ability to simultaneously scale commercialization while running multiple trials.

Deep ongoing operating and net losses

Large operating and net losses driven by high operating costs leave the company far from profitability. Even with strong gross margins on limited sales, the current cost base and lack of recurring revenue create uncertainty around reaching sustainable profitability without sizable growth or expense base reduction.

Nasdaq listing compliance risk and limited cash runway

A notice of non-compliance with minimum bid price and modest cash on hand create near-term execution risk. Potential delisting would impair liquidity and access to capital, and low cash increases urgency for dilutive financings or rapid commercial scaling to avoid operational strain.

Citius Pharmaceuticals Business Overview & Revenue Model

Company Description

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Citius Pharmaceuticals’ business model has historically centered on advancing product candidates through development and regulatory pathways rather than generating recurring revenue from an established portfolio of commercialized products. Its future product-related revenue, if any, would typically come from (a) product sales after FDA approval and launch (either through its own commercialization infrastructure or via a commercial partner), and/or (b) licensing arrangements that can include upfront payments, milestone payments tied to development/regulatory/commercial events, and royalties on partner sales. Specific, current recurring revenue streams from product sales and the material terms of significant revenue-generating partnerships are null (not available here without citing current filings/press releases). In practice, companies at this stage often fund operations primarily through equity offerings, warrants, and other financing activities; however, the company’s exact current mix of financing vs. operating revenue is null here without up-to-date source data.

Citius Pharmaceuticals Financial Statement Overview

Summary

Despite very low leverage and sizable equity, CTXR is deeply unprofitable with large operating/net losses and persistent cash burn (TTM operating cash flow/free cash flow about -$34.8M), with limited recurring revenue and weak earnings visibility.

Income Statement

CTXR remains firmly loss-making. In TTM (Trailing-Twelve-Months), the company generated ~$3.9M of revenue with strong gross profitability (~76% gross margin), but operating costs are far larger than revenue, driving a very large operating loss (EBIT of about -$37.5M) and net loss (about -$37.1M), implying deeply negative profitability. Annual periods from 2021–2025 show little to no recurring revenue, and losses have not shown a sustained improving trajectory, which keeps overall earnings quality and visibility weak.

Balance Sheet

The balance sheet is a relative strength. Leverage is very low (TTM debt-to-equity ~0.01), and equity remains sizable (~$80.0M TTM), providing financial flexibility versus many early-stage biotech peers. However, negative returns on equity (around -54% TTM) reflect continued losses and ongoing value dilution risk if the company needs additional capital to fund operations.

Cash Flow

Cash generation is weak with persistent cash burn. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow were both about -$34.8M, and the business is not self-funding. While the cash burn rate has fluctuated year to year (with some periods showing improvement and others worsening), the overall pattern remains consistently negative, increasing dependence on financing or successful commercialization milestones.

Breakdown	TTM	Sep 2025	Sep 2024	Dec 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	3.94M	0.00	0.00	0.00	0.00	0.00
Gross Profit	2.42M	-214.25K	-209.61K	-194.32K	-179.68K	-164.87K
EBITDA	-36.68M	-38.20M	-38.64M	-31.77M	-32.88M	-22.88M
Net Income	-35.89M	-37.43M	-39.14M	-32.54M	-33.64M	-23.13M
Balance Sheet
Total Assets	140.39M	130.94M	116.65M	103.61M	114.00M	142.43M
Cash, Cash Equivalents and Short-Term Investments	7.72M	4.25M	3.25M	26.48M	41.71M	70.07M
Total Debt	1.83M	1.81M	262.87K	481.25K	678.23K	855.47K
Total Liabilities	46.92M	53.41M	42.55M	12.18M	10.57M	9.65M
Stockholders Equity	79.96M	67.55M	70.08M	90.83M	102.83M	132.18M
Cash Flow
Free Cash Flow	-34.84M	-26.55M	-28.20M	-29.06M	-28.36M	-64.26M
Operating Cash Flow	-34.84M	-26.55M	-28.20M	-29.06M	-28.36M	-24.25M
Investing Cash Flow	-10.15M	-5.75M	-5.00M	0.00	0.00	-40.01M
Financing Cash Flow	51.61M	33.30M	9.97M	13.83M	0.00	120.47M

Citius Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 0.86 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.82, and below the 200-day MA of 1.16, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 41.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.

Citius Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTXR	50 Neutral	$18.47M	-0.51	-54.40%	―	―	18.73%
PASG	46 Neutral	$22.55M	-0.82	-87.18%	―	―	38.42%
MRKR	44 Neutral	$22.34M	―	-92.35%	―	-12.99%	-13.67%
SYBX	40 Underperform	$7.68M	-13.72	-27.54%	―	-100.00%	93.62%

Citius Pharmaceuticals Corporate Events

Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data

On March 10, 2026, Citius Oncology reported positive topline results from an investigator-initiated Phase 1 trial led by the University of Pittsburgh evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gynecologic cancers. The dose-escalation study, which enrolled heavily pretreated patients with limited options, found no unexpected safety signals or serious immune-related adverse events across dose levels and established a recommended dose for further study.

Among 21 evaluable patients, the trial showed a 24% objective response rate and a 48% clinical benefit rate, suggesting that LYMPHIR’s T-regulatory cell depletion may enhance the anti-tumor effect of PD-1 checkpoint inhibition in ovarian and endometrial cancers. While the Phase 1 study was not powered to confirm efficacy, the favorable safety profile and early efficacy signal highlight the potential for LYMPHIR to expand its role beyond cutaneous T-cell lymphoma and could support Citius Oncology’s broader immuno-oncology ambitions if confirmed in later-stage trials.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.94 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data

On March 4, 2026, Citius Oncology reported positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. The study, led by investigators at the University of Minnesota and City of Hope, found LYMPHIR well tolerated with no dose-limiting toxicities and demonstrated effective regulatory T-cell depletion when used to augment standard lymphodepletion.

Among 14 high-risk DLBCL patients, all of whom proceeded to CAR-T infusion with approved commercial products, the trial showed an 86% overall response rate at one month, including 57% complete and 29% partial responses, with one-year progression-free and overall survival of 77% and 84%, respectively. While not powered for definitive efficacy conclusions and using LYMPHIR outside its approved indication, the favorable safety profile and pharmacodynamic data support LYMPHIR’s potential to enhance CAR-T outcomes, reinforcing Citius Oncology’s strategy to expand the drug’s role beyond cutaneous T-cell lymphoma and potentially strengthening its position in the immuno-oncology market.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Citius Pharmaceuticals Posts First Revenue Amid Listing Risk

On February 9, 2026, Citius Pharmaceuticals received notice that its Nasdaq-listed common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance or face potential delisting, though trading under the CTXR symbol continues while the company evaluates remedies. Separately, on February 13, 2026, the company reported its first-ever revenue of $3.9 million from LYMPHIR sales following the drug’s December 2025 U.S. launch, alongside $20.9 million in equity financing, reduced R&D spending, and a narrower quarterly net loss, underscoring an early but pivotal commercial inflection amid ongoing Nasdaq listing risk and continued investment in its late-stage pipeline.

Citius Oncology’s LYMPHIR launch has seen early U.S. physician uptake via a nationwide distributor network, supported by an AI-enabled commercial platform targeting a concentrated prescriber base in this rare cancer market. Management is also pursuing international access through named patient programs in Europe and the Middle East and exploring broader clinical utility via investigator-initiated combination studies, moves that could expand LYMPHIR’s addressable market and reinforce Citius Oncology’s competitive position.

For the quarter ended December 31, 2025, Citius reported $7.7 million in cash and cash equivalents, with operations bolstered by capital raised at both the parent and oncology subsidiary levels. While general and administrative and stock-based compensation expenses increased, the company’s net loss narrowed year over year, reflecting the initial contribution from product revenue and tighter R&D spending as it engages with the FDA on next steps for Mino-Lok and Halo-Lido.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.